Evaluating neurotoxic effects: Epidemiological, epistemic, and economic issues

Human Developmental Neurotoxicology

Volumn , Issue , 2006, Pages 499-507

  Needleman, Herbert L ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77957922362     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (24)

1. Weiss B, Laties V. Behavioral pharmacology: the current status. FASEB Monographs, Bethesda MD 1975.
2. Spyker J, Sparber S, Goldberg A. Subtle consequences of methylmercury exposure: behavioral deviations in offspring of treated mothers. Science 1972; 177:621-623.
3. Jones K, Smith D, Ulleland C, Streissguth A. Patterns of malformation in offspring of chronic alcoholic mothers. Lancet 1973; 1:1267-1272.
4. Byers RK, Lord EE. Late effects of lead poisoning on mental development. Am J Dis Child 1943; 66:471-183.
5. National Research Council. Measuring Lead Exposure in Infants, Children, and Other Sensitive Populations Washington D.C. Washington: National Academy of Sciences Press, 1993.
6. Fisher RA. Statistical Methods for Research Workers. Edinburgh: Oliver & Boyd, 1925.
7. Schwartz J. Low-level lead exposure and children's IQ: a meta-analysis and search for a threshold. Environ Res 1994; 65:42-55.
8. Needleman HL, Gatsonis C. Low level lead exposure and the IQ of children. JAMA 1990; 263:673-678.
9. Pocock SJ, Smith M, Baghurst P. Environmental lead and children's intelligence: a systematic review of the epidemiological evidence. BMJ 1994; 309:11197-11898.
10. Needleman HL. Clamped in a straitjacket: the insertion of lead into gasoline. Environ Res 1997; 74:95-103.
11. Washburn J. The kept university. The Atlantic Mon 2000; March.
12. Krimsky S. Science and the Private Interest. Lanham, MD: Rowman-Littlefield Publishing Co, 2003.
13. Bekelman J, Li Y, Gross C. Scope and impact of financial conflicts of interest in biomedical research. JAMA 2003; 289:454-465.
14. Stelfox H, Chua G, O'Rourke G, Detsky A. Conflict of interest in the debate over calcium antagonists. N Engl J Med 1998; 338:101-106.
15. Shulman K, Seils D, Timbie JW, et al. A national survey of provisions in clinical-trial agreements between medical schools and industry sponsors. N Engl J Med 2002; 347:1335-1341.
16. United States Environmental Protection Agency. Air Quality Criteria for Lead. Environmental Criteria and Assessment Office, EPA 600/8/-83-028A.
17. Ernhart CB, Landa B, Schell NB. Subclinical levels of lead and developmental deficit A multivariate followup reassessment. Pediatrics 1981; 67:911-919.
18. Smith M, Delves T, Lansdown R, Clayton B, Graham P. The effects of lead exposure on urban children: The Institute of Child Health: Southampton Study. Dev Med Child Neurol 1983; 25:1-54.
19. Needleman HL. The removal of lead from gasoline: historical and personal reflections. Environ Res 2000; 84:20-35.
20. Grosse SD, Matte TD, Schwartz J, Jackson RJ. Economic gains resulting from the reduction in children's exposure to lead in the United States. Environ Health Perspect 2002; 110:563-569.
21. Patterson CC. Contaminated and natural environments of man. Arch Environ Health 1965; 11:344-360.
22. Canfield RL, Henderson CR, Cory-Slechta DA, Cox C, Jusko TA, Lanphear BP. Intellectual impairment in children with blood lead concentrations below 10 micrograms per deciliter. N Engl J Med 2003; 348:1517-1526.
23. Lanphear BP, Dietrich KN, Auinger P, Cox C. Cognitive deficits associated with blood lead concentrations < 10 (g/dL in U.S. children and adolescents. Publ Health Rep 2000; 111:521-529.
24. Bellinger DC, Needleman HL. Intellectual impairment and blood lead levels. N Engl J Med 2003;349-500.